Proteome Sciences

Executive Summary

Proteome Sciences is a specialized Contract Research Organization (CRO) based in London, UK, with over 30 years of experience in mass spectrometry-based proteomics. The company is the exclusive manufacturer of Tandem Mass Tags (TMT) reagents, a critical isobaric tagging technology used for protein biomarker discovery and validation. These reagents are distributed globally through ThermoFisher Scientific, giving Proteome Sciences a unique revenue stream and strategic partnership. The company provides end-to-end proteomic services to top biopharma clients, supporting precision medicine from early discovery to clinical research. Despite being private and relatively small, its proprietary TMT technology creates a competitive moat and recurring revenue from reagent sales. Looking ahead, Proteome Sciences is well-positioned to benefit from the growing demand for proteomics in drug development and diagnostics. The company's expertise in biomarker discovery aligns with the industry shift toward personalized medicine. Key growth drivers include expansion of its service offerings, deeper penetration into pharmaceutical partnerships, and potential applications in clinical diagnostics. While financial details are limited, the company's niche technology and established distribution channel provide a solid foundation for sustained growth. However, dependency on ThermoFisher and the competitive CRO landscape pose risks.

Upcoming Catalysts (preview)

• Q3 2026New major pharma partnership for TMT-based biomarker discovery60% success
• H1 2027Launch of next-generation TMT reagent with improved multiplexing capacity50% success
• Q4 2026Expansion into clinical diagnostic services leveraging TMT technology40% success